Low Dose Methoxyflurane and Out-Patient Aesthetic Surgery and Facial Filler

Overview

The aim of the study is to generate real-world evidence on the effectiveness, safety and additional parameters of low dose methoxyflurane (PENTHROX®) in: aesthetic surgeries (eg. hair transplant, upper blepharoplasty, otoplasty, upper brow lift, and mentoplasty) and facial filler injections [eg. hyaluronic acid (HA) and Sculptra®] in an outpatient aesthetic practice. This will be an open-label study, with a total of 60 patients undergoing a planned outpatient aesthetic surgery or filler injection (30 patients in each group).

Full Title of Study: “An Open-Label Study to Assess the Efficacy and Safety of Low Dose Methoxyflurane (PENTHROX®) for Pain Control During Outpatient Aesthetic Surgeries and Facial Filler Injections”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2021

Interventions

  • Drug: Methoxyflurane
    • Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.

Arms, Groups and Cohorts

  • Other: Penthrox
    • Low Dose Methoxyflurane

Clinical Trial Outcome Measures

Primary Measures

  • Assessing patient satisfaction
    • Time Frame: through study completion, an average of 1 year
    • Global assessment of medication performance (gmp)

Participating in This Clinical Trial

Inclusion Criteria

1. Conscious adult patients: ≥ 18 years of age 2. Patient is scheduled for an outpatient anesthetic surgery (eg. hair transplant, upper blepharoplasty, otoplasty, upper brow lift, and mentoplasty) or a facial filler injection (eg. HA, and Sculptra®). 3. Patient should understand the nature of the study and provide written informed consent 4. Patient is able to follow all study requirements and procedures and complete required questionnaires Exclusion Criteria:

1. An altered level of consciousness, due to any cause, including head injury, drugs, or alcohol 2. Clinically significant renal impairment 3. Women of child bearing potential who are pregnant or peri partum, including labour 4. A history of liver dysfunction after previous methoxyflurane use or other halogenated anesthetics 5. Hypersensitivity to methoxyflurane or other halogenated anesthetics, or to butylated hydroxytoluene 6. Known or genetically susceptible to malignant hyperthermia or a history of severe adverse reactions in either patient or relatives 7. Clinically evident or potential hemodynamic instability as per the opinion of the investigator 8. Clinically evident respiratory impairment as per the opinion of the investigator 9. Prior treatment with PENTHROX® within 3 months

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Verso Surgery Centre
  • Provider of Information About this Clinical Study
    • Sponsor

References

Romagnoli A, Busque L, Power DJ. The "analgizer" in a general hospital: a preliminary report. Can Anaesth Soc J. 1970 May;17(3):275-8. doi: 10.1007/BF03004607. No abstract available.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.